Disorder | Marginal Dose (50% IDL) | Comments |
AVM | 15-25Gy |
varies by size and location goal should be 24Gy (15-16 min) see AVM chart |
Acoustic Neuroma | 11-15Gy |
13Gy is usual (11-12 if 3cm) 12-13Gy at Cleveland |
Meningioma | 11-18Gy |
atypical (50-56Gy EBT + 12-16Gy) malignant (60Gy EBT + 12-16Gy) 14-15Gy goal |
Metastases | 14-24Gy |
varies by size or combined with whole brain (see below) |
Glial Tumors | 12-20Gy |
EBT 55-60 Gy + 15.5 - 16Gy |
Trigeminal Neuralgia | 40Gy |
80Gy maximum |
Thalamotomy | 60-70Gy |
120-140Gy maximum |
Pituitary | 11-25Gy |
functional 16-25Gy nonfunctional 12-16Gy limit optic nerve and chiasm to 8Gy |
The dose ranges above are from U Pitt. Other sites (e.g. Cleveland Clinic) have standard doses: acoustic neuroma of 12-13Gy, meningioma 14-15Gy if < 35mm and at least 5mm from the optic chiasm, and pituitary15-20Gy (higher if functional.) Volume is critical so in an AVM consider dose adjustments like: < 2cc (24Gy) 2.1- 5cc (22-23Gy) 5-8cc (21Gy) 8 - 13.5cc (18Gy) and > 13.5cc. The AVM (Pitt) data used 12Gy volume to predict toxicity and volumes up to 20cc had a low risk (< 10%) except brain stem sites. See the tables on doses for single fraction or three fractions or five fractions |
Size | Pit | RTOG | Other |
2cm | 20Gy | 24Gy | 24Gy |
2.1-3cm | 15-16Gy | 18Gy | 22-24 |
3.1-4cm | 13.5 - 14Gy | 15Gy | 16Gy |
whole + RS | 16Gy | 18Gy-20Gy |
Tumor Diameter | Prescription Dose (40-60%IDL) |
< 15mm | 25Gy |
15- 20mm | 20-25Gy |
20-25mm | 20Gy |
25-30mm | 18Gy |
>30mm | don't treat |
|
||||||||||||||||||||||||||||||
the dose for a brain metastases may be better chosen based on the volume rather than the diameter. For small volume lesions (up to 4-5 cc) full doses can probably be given (e.g. 22-24Gy, if over the motor strip 22Gy) for somewhat larger (5-8cc) the dose can be dialed down a bit (20-22Gy, but it may be useless to treat radioresistant mets to < 20Gy) for larger lesions (>8cc) then lower doses (16Gy) may be necessary. There are some studies with brain mets that showed better results with a dose of at least 20Gy in terms of increased survival. There may be still be a palliative benefit gained even if lower doses have to be used. | ||||||||||||||||||||||||||||||
|
|
Diameter (mm) | Volume (cc) | Gy (1% K) | Gy (3% ILF) |
12.5 | 1.02 | 27.5 | 34 |
15.0 | 1.77 | 25.0 | 29 |
17.5 | 2.81 | 22.5 | 23 |
20.0 | 4.10 | 20.0 | 18 |
22.5 | 5.96 | 18.7 | 16.5 |
25.0 | 8.18 | 17.5 | 14.5 |
27.5 | 10.89 | 16.5 | 13.5 |
30.0 | 14.14 | 15.0 | 13 |